PMID- 32725160
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20210823
IS  - 1535-2900 (Electronic)
IS  - 1079-2082 (Linking)
VI  - 77
IP  - 21
DP  - 2020 Oct 14
TI  - Best practices for safe use of SGLT-2 inhibitors developed from an expert panel 
      Delphi consensus process.
PG  - 1727-1738
LID - 10.1093/ajhp/zxaa243 [doi]
AB  - PURPOSE: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated 
      glycemic efficacy and cardiovascular and renal benefits in people with type 2 
      diabetes mellitus (T2DM). However, they are also associated with serious adverse 
      events (AEs), but little consensus exists for clinicians regarding AE management. 
      This study aimed to develop a list of best practices for the safe use and 
      monitoring of SGLT-2 inhibitors in people with T2DM. METHODS: A 15-member 
      interprofessional panel was surveyed in a four-round Delphi process. Panelists 
      were asked to comment on and rank statements regarding initial prescribing 
      considerations and actions for minimizing and managing eight specific AEs and a 
      broad category for other AEs. In the final round, panelists selected if the 
      statements should be considered a best practice specific to SGLT-2 inhibitors, a 
      best practice for general safe medication use in T2DM, or if the statement should 
      not be considered as a best practice for safe medication use. RESULTS: Consensus 
      was achieved for 36 best practice statements specific to SGLT-2 inhibitors and 24 
      statements as general best practices for safe medication use. Fifty-six percent 
      of the best practice statements for SGLT-2 inhibitors related to managing and/or 
      preventing hypotension, urinary tract infections, and genital infections. The 
      general best practices for safe medication use primarily focused on medication 
      histories, past medical history considerations, physical exam components, and 
      patient education. CONCLUSION: A list of best practice statements was developed 
      using the Delphi method, which can be utilized by clinicians to guide the safe 
      use and monitoring of SGLT-2 inhibitors in people with T2DM.
CI  - (c) American Society of Health-System Pharmacists 2020. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Pamulapati, Lauren G
AU  - Pamulapati LG
AD  - Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth 
      University School of Pharmacy, Richmond, VA.
FAU - Rochester-Eyeguokan, Charmaine D
AU  - Rochester-Eyeguokan CD
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy, Baltimore, MD.
FAU - Pincus, Kathleen J
AU  - Pincus KJ
AD  - Department of Pharmacy Practice and Science, University of Maryland School of 
      Pharmacy, Baltimore, MD.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Health Syst Pharm
JT  - American journal of health-system pharmacy : AJHP : official journal of the 
      American Society of Health-System Pharmacists
JID - 9503023
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Consensus
MH  - Delphi Technique
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Monitoring/standards
MH  - Drug Prescriptions/standards
MH  - Humans
MH  - Hypotension/chemically induced/diagnosis/prevention & control
MH  - Patient Education as Topic/standards
MH  - Practice Guidelines as Topic/*standards
MH  - Reproductive Tract Infections/chemically induced/diagnosis/therapy
MH  - Sodium-Glucose Transporter 2 Inhibitors/administration & dosage/*adverse effects
MH  - Urinary Tract Infections/chemically induced/diagnosis/prevention & control
OTO - NOTNLM
OT  - Delphi technique
OT  - SGLT2 protein
OT  - adverse drug event
OT  - diabetes mellitus
EDAT- 2020/07/30 06:00
MHDA- 2021/08/24 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 5877701 [pii]
AID - 10.1093/ajhp/zxaa243 [doi]
PST - ppublish
SO  - Am J Health Syst Pharm. 2020 Oct 14;77(21):1727-1738. doi: 10.1093/ajhp/zxaa243.